Actively Recruiting
Evaluating Chemotherapy Before Surgery Versus After Surgery for Upper Tract Urothelial Cancer A Multicenter Randomized Feasibility Trial
Led by University Health Network, Toronto · Updated on 2026-10-06
14
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying upper tract urothelial cancer UTUC, a rare cancer affecting the lining of the kidney or ureter. This trial aims to evaluate whether giving chemotherapy before surgery neoadjuvant chemotherapy improves outcomes compared to the standard approach of surgery followed by chemotherapy adjuvant chemotherapy. This is the first Canadian clinical trial to test this treatment timing in UTUC and to see if enough patients can be enrolled for such a study. Participants will be randomly assigned to one of two groups. One group receives gemcitabine and cisplatin chemotherapy every 3 weeks for up to four cycles before undergoing surgery to remove part or all of the kidney and ureter. The other group has surgery first, then chemotherapy afterward. Patients with reduced kidney function may receive carboplatin instead of cisplatin. Chemotherapy dosing and scheduling follow standard protocols for these drugs. During the study, participants will be monitored to assess recruitment feasibility and treatment effects. Researchers will track disease-free survival, the rate of complete tumor response, and enrollment metrics over 24 to 36 months. Safety, organ function, and treatment tolerance will be evaluated through laboratory tests and clinical assessments. The study will continue until December 2028, with participants undergoing surgery, chemotherapy, and follow-up visits as scheduled.
CONDITIONS
Brief Title
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)
Research Team
E
Emily Hickey
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here